Technology

Samsung BioAccelerates 2.7 Trillion Won Polypeptide Acquisition… Secures 87.9% Stake

Minji Son
2026-10-13 15:26:02
[Edaily Reporter Minji Son ] SAMSUNG BIOLOGICS(207940), a global peptide contract development and manufacturing organization (CDMO), recorded a subscription rate of 87.88% in the interim results of its tender offer. Since this exceeds the minimum threshold of 66.7% required for the transaction to be accepted, it is now highly likely that the acquisition process will proceed as scheduled.

On the 13th, SAMSUNG BIOLOGICS announced preliminary interim results for the tender offer for Polypeptide Group shares, which ran from the 15th of last month through the previous day.

The tender offer was conducted through Samsung Peptide, a subsidiary of the special purpose company (SPC) established to acquire Polypeptide Group. It targeted all 33,016,411 issued shares—excluding treasury shares—at a price of 44.31 Swiss francs per share.

According to the preliminary tally, a total of 29,014,418 shares were tendered. This represents 87.88% of the shares subject to the tender offer and 87.59% of Polypeptide Group’s total issued shares. All 18,375,000 shares held by the previous largest shareholder, Draupnir Holdings, were also tendered.

These results are preliminary; the final interim results, verified by an independent auditor, are scheduled to be announced on the 16th. SAMSUNG BIOLOGICS plans to accept additional subscriptions from the 19th to the 30th and then finalize the transaction following approval from relevant authorities in Europe, India, Australia, and Brazil. The company aims to complete the final acquisition by the end of November.

SAMSUNG BIOLOGICS signed an acquisition agreement with Polypeptide Group last July. The acquisition price of 1.46 billion Swiss francs (approximately 2.7 trillion won) marks the largest merger and acquisition (M&A) deal in South Korea’s pharmaceutical and biotech industry.

With this acquisition, SAMSUNG BIOLOGICS will expand its CDMO business scope to include peptides, in addition to its existing antibody drugs, messenger RNA (mRNA), and antibody-drug conjugates (ADCs).

Peptides are used as key raw materials in diabetes and obesity treatments, and production demand is expected to grow in line with the expansion of the related therapeutic market. According to analyses by global investment banks (IBs) and others, the global obesity treatment market is projected to grow to as much as $150 billion (approximately 200 trillion won) by around 2035.

SAMSUNG BIOLOGICS plans to expand its business foundation by combining its accumulated experience in the design and operation of large-scale production facilities with the peptide development and production capabilities of its Polypeptide Group. The company also plans to consider expanding its production facilities in the future based on market demand.

Economy

Corporation

IT·Science

Economy

Samsung Electronics and Hanwha Group’s Cash Reserves Surpass 329 Trillion Won… Expanding Investment and Shareholder Returns Amid AI Boom

Driven by the boom in artificial intelligence (AI) semiconductors, the combined cash reserves of SamsungElectronics and SK hynix have surpassed 329 trillion won. This represents an increase of more th…
2026-11-08 17:18:25

Corporation

The Auto Industry’s EV Dilemma… Volkswagen, Which Hit the Gas, Is Crying, While GM, Which Hit the Brakes, Is Smiling

U.S.-based General Motors (GM) posted an operating profit of approximately $3.6 billion (4.9 trillion won) in the third quarter of this year after slowing the pace of its electric vehicle (EV) investm…
2026-11-08 17:42:31

IT·Science

Following LG Corp. and Naver, Now Samsung and Kakao… Government Sets Out to Develop AI Itself

The government has begun developing public AI services by recruiting private-sector AI experts into its policy organizations and even directly hiring developers. Lee Ji-soo, a former executive at Sams…
2026-11-08 14:16:00